Contribution of Skin Color in Stabilization of Active Cases of Vitiligo by Narrow Band UVB

• Status: Unknown status
• Trial end date: 2019-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Vitiligo is a disease in which autoimmunity plays a major role. Multiple treatment options are available, of which narrow-band UVB is a cornerstone, acting through immunosuppression and repigmentation by stimulating reservoir melanocytes.

It's expected that this immunsupression is lower in darker skin types, where increased basal melanin might act as a barrier.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Collaborators: Alexandria University; Assiut University; Cairo University; Menia University; Suez Canal University
• Treatments: BB 1101; Dexamethasone; Dexamethasone acetate

Criteria

Inclusion Criteria:

• Active cases of non-segmental vitiligo, VIDA +2 or more.

• All skin types

• Age above 6 years, both sexes.

Exclusion Criteria:

• Contraindications to NB-UVB ( photosensitive skin disorders, skin malignancy, patients on photosensitizing medications)

• Contraindications to mini-pulse steroid therapy (uncontrolled diabetes or hypertension, peptic ulcer)

• Stable disease (VIDA 0 & -1) and activity more than 6 months ago (VIDA +1).

• The use of other treatment for vitiligo during the 3 months previous to enrollment.